BioCentury
ARTICLE | Clinical News

MLE4901: Phase IIb started

August 22, 2016 7:00 AM UTC

Millendo began a double-blind, placebo-controlled, international Phase IIb trial to evaluate 40, 60 and 80 mg oral MLE4901 twice daily for 28 weeks in about 220 patients. The company has exclusive, wo...